Regulatory considerations for development of bioanalytical assays for biotechnology products
Patrick G Swann1, Marjorie A Shapiro
1Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drugs Evaluation & Research, U.S. Food & Drug Administration, MD, USA.
Abstract:
Ligand-binding assays are the predominant method used for determination of concentrations of biotechnology products in serum or other matrices, as well as for the determination of antidrug antibodies in nonclinical and clinical studies. The challenges regarding the design and validation of these assays are well understood. The US FDA published a Guidance for Industry on Bioanalytical Method Validation and a Draft Guidance for Industry on Assay Development for Immunogenicity Testing of Therapeutic Proteins. The purpose of this article is to highlight specific elements in these guidance documents that should also apply to new methods, discuss the application of new generation ligand-binding methods and LC-MS for these purposes and provide a scientific and regulatory perspective on the specific challenges assessing the pharmacokinetics and immunogenicity of monoclonal antibodies.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Upstream Processing
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioequivalence studies: Biowaivers
Clinically Relevant Drug Product Specifications: Methods of Establishment
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems


